Core Viewpoint - The stock of Insilico Medicine (03696) surged nearly 15% in early trading, reaching a high of 54 HKD, which represents an increase of over 124% from its IPO price of 24.05 HKD [1] Group 1: Clinical Trials and Drug Development - Insilico Medicine announced the completion of the first dosing of its innovative PHD inhibitor ISM5411 in a Phase IIa clinical trial named BETHESDA [1] - The candidate drug, developed with the company's proprietary generative AI platform Pharma.AI, is designed for the treatment of inflammatory bowel disease (IBD) and has recently received official approval for its generic name Garutadustat from the USAN Council [1] Group 2: Strategic Partnerships - On January 5, Insilico Medicine announced a long-term collaboration with SIVAN to develop anti-tumor drugs, with a total collaboration amount of 888 million USD [1] - Insilico Medicine is eligible to receive up to 32 million USD in upfront payments and milestone payments for recent research developments [1] - The company will utilize its self-developed AI platform Pharma.AI to focus on challenging targets in the anti-tumor field, identifying and developing new therapeutic drugs, while SIVAN will co-share the research costs and lead subsequent clinical validation and commercialization processes [1]
港股异动 | 英矽智能(03696)早盘涨近15% 治疗炎症性肠病候选药物IIA期临床试验完成首例给药